• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
leishmaniasis icon

Visceral leishmaniasis

Symptoms, transmission, and current treatments for visceral leishmaniasis

Home > Diseases
leishmaniasis icon

Visceral leishmaniasis

Symptoms, transmission, and current treatments for visceral leishmaniasis

  • Overview
  • Facts
  • Projects & achievements
  • Target product profiles

What is visceral leishmaniasis? 

Visceral leishmaniasis, the most severe form of leishmaniasis also known as kala-azar, is a life-threatening disease caused by Leishmania parasites which are transmitted by female sandflies. Visceral leishmaniasis causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. People with both visceral leishmaniasis and HIV are particularly difficult to cure.

Visceral leishmaniasis affects the poorest of the poor, being associated with malnutrition, population displacement, poor housing, a weak immune system, and lack of financial resources. The disease is also linked to environmental changes such as deforestation, building of dams, irrigation schemes, and urbanization.

A skin condition known as post-kala-azar dermal leishmaniasis (PKDL) may appear months or years after successful treatment for visceral leishmaniasis.  While it is not life-threatening, PKDL can be disfiguring and stigmatizing. People with PKDL can still transmit visceral leishmaniasis, complicating efforts to eliminate the disease.

What is the impact of visceral leishmaniasis?

  • Over 600 million at risk worldwide
  • 50,000-90,000 new cases per year
  • 5,710 deaths in 2019
  • More than 100x higher risk of developing active visceral leishmaniasis in people living with HIV
  • 5-10% of people treated for visceral leishmaniasis develop PKDL
  • In 2020, more than 90% of new cases reported to WHO occurred in 10 countries: Brazil, China, Ethiopia, Eritrea, India, Kenya, Somalia, South Sudan, Sudan, and Yemen. 

What are the current drugs for visceral leishmaniasis?

Existing drugs have serious drawbacks in terms of safety, resistance, stability, and cost. They have low tolerability, long treatment duration when used individually, and are difficult to administer:

Pentavalent antimonials (sodium stibogluconate and meglumine antimoniate)

  • 30-day treatment by infusion, if given on its own
  • Resistance has been seen in areas where the disease is very common
  • Toxic, with risk of serious cardiotoxicity leading to death

Liposomal amphotericin B

  • Much safer and highly effective in some regions: a single 10mg/kg infusion has a cure rate of greater than 90% in Asia
  • Expensive and needs to be stored in a fridge

Miltefosine

  • 28-day, twice-a-day oral drug
  • Nausea and vomiting are common side effects that may affect adherence to the four-week treatment
  • Cannot be used during pregnancy
  • Not available in many countries

Paromomycin

  • Three weeks of painful intramuscular injections
  • Low-cost formulation
  • Associated with toxic effects on the kidneys and ears
  • Limited efficacy when used on its own in East Africa

Treatment responses to visceral leishmaniasis vary by region, and therefore the recommended treatments also differ. Together with our partners, we have worked to improve existing treatments by developing improved combination treatments for Africa and new treatments for Asia. We have also worked to build evidence for safer treatment alternatives in Latin America.

What new treatments for visceral leishmaniasis are needed?

WHO has set the target date for the elimination of this disease from the Indian subcontinent to 2020. In order to achieve this goal and improve treatment in other regions, people with visceral leishmaniasis need treatments that are oral, safe, effective, low cost, and short course.

What visceral leishmaniasis treatments are we working on?

We aim to make treatments safer, shorter and more affordable and effective. In the short term, better treatment regimens are being developed using existing drugs. In the long term, the goal is to develop an entirely new generation of all-oral drugs.

Find out about our work developing treatments for visceral leishmaniasis

How do you get visceral leishmaniasis? 

  • Insect bites: Leishmania parasites are transmitted through the bites of infected female phlebotomine sandflies
  • Poor housing and domestic sanitary conditions may increase sandfly breeding and resting sites
  • Malnutrition increases the risk that an infection will progress to full-blown disease

What are the symptoms of visceral leishmaniasis? 

Visceral leishmaniasis has symptoms that occur progressively over a period of weeks or even months:

  • prolonged fever
  • enlarged spleen and liver
  • substantial weight loss
  • progressive anaemia
  • usually fatal if untreated

How is visceral leishmaniasis diagnosed? 

Visceral leishmaniasis is diagnosed by combining observations from a physical exam by a health worker with parasitological or antibody-based diagnostics. The main signs are prolonged fever, weight loss, enlargement of the spleen, and anemia.

Other approaches for visceral leishmaniasis diagnosis involve antibody detection using the rK39 rapid diagnostic test (RDT) and the alternative Direct Agglutination Test (DAT) to confirm infection. People with VL symptoms but negative diagnostic results are referred to hospitals or clinics where microscopic examination of tissue aspirate (spleen, bone marrow, or lymph node) is available. Spleen aspiration, if  performed incorrectly, can cause fatal bleeding.

Easy-to-use, non-invasive diagnostics that can be used in remote settings by health workers with limited training are critical to improving patient care and visceral leishmaniasis control. We are part of a consortium project, AfriKADIA, which hopes to improve visceral leishmaniasis testing in eastern Africa. One of the project partners, FIND, is evaluating less invasive tests in Ethiopia, Kenya, Sudan, and Uganda to determine the best approach to diagnosis.

More information 

  • WHO factsheet
  • AfriKADIA project

Last updated: March 2022

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Healthcare workers in a hospital

COVID-19

Devasting and deadly to many, there’s too little research to help the most vulnerable

We’re accelerating research by coordinating clinical trials in low-resource settings and bringing together partners

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Sleeping sickness

Chagas disease

Cutaneous leishmaniasis

Hepatitis C

Visceral leishmaniasis

COVID-19

Filaria: river blindness

Cryptococcal meningitis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo